title: Weekly doxorubicin in the treatment of metastatic breast carcinoma.
abstract: The introduction of aggressive combination chemotherapy has not been accompanied by any significant prolongation of survival in metastatic breast carcinoma. Hence, there is a need of less toxic but--in terms of palliation--effective chemotherapeutic regimens. This paper concerns 50 patients with progressive metastatic breast carcinoma who were treated with weekly bolus injections of doxorubicin (15-20 mg). All patients were followed until disease progression. A partial response with a mean duration of 6 months was achieved in 7 patients (14%). In addition, stabilization of disease was observed in 24 patients (48%) during 2-34 months. The toxicity was generally mild. It is concluded that weekly doxorubicin with fairly low doses is a moderately effective treatment in stage IV breast carcinoma. It is devoid of severe toxicity which makes it useful even in old and debilitated patients.
authors: Department of General Oncology, Karolinska Hospital, Stockholm, Sweden.
authors: U
authors: U
authors: Nylén
authors: E
authors: E
authors: Baral
authors: G
authors: G
authors: Svane
authors: L E
authors: LE
authors: Rutqvist
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000188:drug therapy*; D002277:Carcinoma / Q000188:drug therapy*; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis
chemical_list: D004317:Doxorubicin